Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30810326 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1HPGDNPSR1POLB | |
| SCHEMBL2351331 | 0.85 | POLB (0.48) | KDM4EALDH1A1HPGDNPSR1POLB | |
| SCHEMBL1530644 | 0.84 | KDM4E (0.45) | KDM4EALDH1A1HPGDNPSR1POLB | |
| SCHEMBL440813 | 0.84 | HSD17B10 (0.47) | KDM4EALDH1A1HPGDPOLBPKM | |
| SCHEMBL4871213 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1HPGDNPSR1POLB | |
| SCHEMBL12345885 | 0.81 | KDM4E (0.46) | KDM4EALDH1A1HPGDNPSR1POLB | |
| SCHEMBL19348178 | 0.81 | KDM4E (0.45) | KDM4EALDH1A1NPSR1GAAPKM | |
| SCHEMBL4870888 | 0.81 | GALK1 (0.49) | KDM4EALDH1A1HPGDNPSR1POLB | |
| SCHEMBL4123488 | 0.81 | HSD17B10 (0.49) | KDM4EALDH1A1HPGDNPSR1POLB | |
| SCHEMBL29046678 | 0.80 | CYP3A4 (0.53) | KDM4EALDH1A1HPGDNPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4583870-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | Mito Biopharma, LLC (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054766-A2 | MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC DISEASES AND CANCER | MITO BIOPHARMA, LLC (US) | 2024-03-14 | — | — | WO | disclosed |
| US-20080300288-A1 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof | PURDUE RESEARCH FOUNDATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300288-A1 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof | PURDUE RESEARCH FOUNDATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008119028-A1 | ALKENYLDIARYLMETHANES HAVING NITROGEN-CONTAINING CARBOXYLIC ACID DERIVATIVES | CUSHMAN MARK S (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007005531-A2 | ALKENYLDIARYLMETHANES, FUSED ANALOGS AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300288-A1 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof | POLRMT, PNP, TYMS | KDM4E 1291/4885ALDH1A1 276/4885HPGD 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.